3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Waldenstrom Macroglobulinemia
1
Recurrence
1
Lymphoma, Mantle-Cell
1
Leukemia, Hairy Cell
1
Burkitt Lymphoma
1
Interventions
pembrolizumab
110
Specimen Handling
79
Magnetic Resonance Spectroscopy
70
Carboplatin
67
Cisplatin
66
Biopsy
57
Nivolumab
56
Radiotherapy
50
Cyclophosphamide
50
Paclitaxel
48
durvalumab
38
Radiation
37
Gemcitabine
37
olaparib
32
Rituximab
32
Etoposide
32
Dexamethasone
32
Doxorubicin
30
Docetaxel
30
atezolizumab
28
Lenalidomide
27
Ipilimumab
27
Taxes
26
Pemetrexed
25
Bevacizumab
25
Vincristine
24
Cytarabine
24
Prednisone
23
Platinum
23
Radiotherapy, Intensity-Modulated
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
brexucabtagene autoleucel
×
90 days
×
Clear all
NCT02601313
2026-03-18
ZUMA-2
Gilead Sciences
Phase 2
Completed
105 enrolled
33 charts
1 FDA
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts